Recombinant human EPO (rHuEPO) has been used to treat anemia in clinic, and EPO induces cytoprotection via its receptor expressed in tissue against IR injury in different organs such as the lungs, liver, heart, and kidneys. This evidence concerns the gene EPO and anemia (phenotype).